These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10615348)

  • 21. Retention in naltrexone implant treatment for opioid dependence.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Hegstad S; Gossop M; Kristensen O; Waal H
    Drug Alcohol Depend; 2010 Sep; 111(1-2):166-9. PubMed ID: 20570059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Withdrawal syndrome caused by naltrexone in opioid abusers.
    Hassanian-Moghaddam H; Afzali S; Pooya A
    Hum Exp Toxicol; 2014 Jun; 33(6):561-7. PubMed ID: 23690227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Favorable mortality profile of naltrexone implants for opiate addiction.
    Reece AS
    J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unintentional rapid opioid detoxification: case report.
    Singh SM; Sharma B
    Psychiatr Danub; 2009 Mar; 21(1):65-7. PubMed ID: 19270623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methods of detoxification and their role in treating patients with opioid dependence.
    O'Connor PG
    JAMA; 2005 Aug; 294(8):961-3. PubMed ID: 16118388
    [No Abstract]   [Full Text] [Related]  

  • 27. [A review of naltrexone maintenance programs: effectiveness, predictors and profile].
    Madoz-Gúrpide A; Ochoa E; Baca-García E
    Med Clin (Barc); 2002 Sep; 119(9):351-5. PubMed ID: 12356367
    [No Abstract]   [Full Text] [Related]  

  • 28. First, do no harm: naltrexone-accelerated detoxification.
    Gaughwin MD
    Med J Aust; 1999 Nov; 171(9):499. PubMed ID: 10615346
    [No Abstract]   [Full Text] [Related]  

  • 29. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD).
    Albanese AP; Gevirtz C; Oppenheim B; Field JM; Abels I; Eustace JC
    J Addict Dis; 2000; 19(2):11-28. PubMed ID: 10809517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
    J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
    Simon DL
    Conn Med; 1996 Nov; 60(11):683-5. PubMed ID: 8979434
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
    Fishman MJ; Winstanley EL; Curran E; Garrett S; Subramaniam G
    Addiction; 2010 Sep; 105(9):1669-76. PubMed ID: 20626723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence.
    Ramdurg S; Ambekar A; Lal R
    J Sex Med; 2012 Dec; 9(12):3198-204. PubMed ID: 21366875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haight-Ashbury free clinics' drug detoxification protocols--Part 2: Opioid blockade.
    Galloway G; Hayner G
    J Psychoactive Drugs; 1993; 25(3):251-2. PubMed ID: 8258763
    [No Abstract]   [Full Text] [Related]  

  • 35. Emergency department presentations of naltrexone-accelerated detoxification.
    Armstrong J; Little M; Murray L
    Acad Emerg Med; 2003 Aug; 10(8):860-6. PubMed ID: 12896887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concerns about injectable naltrexone for opioid dependence.
    Wolfe D; Carrieri MP; Dasgupta N; Wodak A; Newman R; Bruce RD
    Lancet; 2011 Apr; 377(9776):1468-70. PubMed ID: 21529930
    [No Abstract]   [Full Text] [Related]  

  • 37. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
    Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
    J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies to maximize the efficacy of naltrexone for alcohol dependence.
    O'Malley SS
    NIDA Res Monogr; 1995; 150():53-64. PubMed ID: 8742772
    [No Abstract]   [Full Text] [Related]  

  • 39. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone.
    Herbeck DM; Jeter KE; Cousins SJ; Abdelmaksoud R; Crèvecoeur-MacPhail D
    J Addict Dis; 2016; 35(4):305-314. PubMed ID: 27192330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical treatment of opioid addiction and dependence.
    Ling W; Rawson RA; Compton M
    Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.